真实世界数据复现TORCH试验:COPD药物效果验证
本研究利用英国CPRD数据库(2000-2017)构建历史性队列,通过倾向性评分匹配模拟TORCH试验,评估FP-SAL对COPD急性加重、死亡和肺炎的影响。结果显示,与SAL相比,FP-SAL在加重率、死亡和肺炎上的结果与TORCH试验一致,但与未使用FP-SAL组比较则无法复现安慰剂对照结果。
要点
- 主动对照分析可复现TORCH试验的加重率、死亡和肺炎结果。
- 与未使用FP-SAL组比较无法复现安慰剂对照结果。
- 验证的方法可用于随机对照试验排除人群,支持COPD治疗决策。
核心结论
- 在主动对照分析中,真实世界数据可得到与TORCH试验非常相似的结果,但无法复现安慰剂对照结果。
研究设计与样本
- 历史性队列研究(2000-2017),使用英国CPRD数据库,通过倾向性评分匹配选择FP-SAL暴露组与两个对照组。
主要发现
- FP-SAL vs SAL的加重率比为0.85(95%CI 0.74-0.97),TORCH为0.88(0.81-0.95)。
- FP-SAL vs 无FP-SAL的加重率比为1.30(1.19-1.42),TORCH为0.75(0.69-0.81)。
- FP-SAL vs SAL的死亡率HR为0.93(0.65-1.32),TORCH为0.93(0.77-1.13)。
- FP-SAL vs SAL的肺炎风险比为1.39(1.04-1.87),TORCH为1.47(1.25-1.73)。
临床怎么用
- 验证的主动对照分析方法可用于随机对照试验排除人群,为COPD治疗决策提供证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Real-world data provide the potential for generating evidence on drug treatment effects in groups excluded from trials, but rigorous, validated methodology for doing so is lacking. We investigated whether non-interventional methods applied to real-world data could reproduce results from the landmark TORCH COPD trial.We performed a historical cohort study (2000-2017) of COPD drug treatment effects in the UK Clinical Practice Research Datalink (CPRD). Two control groups were selected from CPRD by applying TORCH inclusion/exclusion criteria and 1:1 matching to TORCH participants, as follows. Control group 1: people with COPD not prescribed fluticasone propionate (FP)-salmeterol (SAL); control group 2: people with COPD prescribed SAL only. FP-SAL exposed groups were then selected from CPRD by propensity score matching to each control group. Outcomes studied were COPD exacerbations, death from any cause and pneumonia.2652 FP-SAL exposed people were propensity score matched to 2652 FP-SAL unexposed people while 991 FP-SAL exposed people were propensity score matched to 991 SAL exposed people. Exacerbation rate ratio was comparable to TORCH for FP-SAL versus SAL (0.85, 95% CI 0.74-0.97 versus 0.88, 0.81-0.95) but not for FP-SAL versus no FP-SAL (1.30, 1.19-1.42 versus 0.75, 0.69-0.81). In addition, active comparator results were consistent with TORCH for mortality (hazard ratio 0.93, 0.65-1.32 versus 0.93, 0.77-1.13) and pneumonia (risk ratio 1.39, 1.04-1.87 versus 1.47, 1.25-1.73).We obtained very similar results to the TORCH trial for active comparator analyses, but were unable to reproduce placebo-controlled results. Application of these validated methods for active comparator analyses to groups excluded from randomised controlled trials provides a practical way for contributing to the evidence base and supporting COPD treatment decisions.
引用
- Wing K, Williamson E, Carpenter JR, et al. Real world effects of COPD medications: a cohort study with validation against results from randomised controlled trials. Eur Respir J. 2021. PMID: 33093119. doi:10.1183/13993003.01586-2020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。